FR2850970B1 - Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique - Google Patents

Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Info

Publication number
FR2850970B1
FR2850970B1 FR0301478A FR0301478A FR2850970B1 FR 2850970 B1 FR2850970 B1 FR 2850970B1 FR 0301478 A FR0301478 A FR 0301478A FR 0301478 A FR0301478 A FR 0301478A FR 2850970 B1 FR2850970 B1 FR 2850970B1
Authority
FR
France
Prior art keywords
specific
application
anticancer agent
chemical derivatives
dna structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0301478A
Other languages
English (en)
French (fr)
Other versions
FR2850970A1 (fr
Inventor
Augustin Hittinger
Thomas Caulfield
Patrick Maillet
Herve Bouchard
Eliane Mandine
Chafke Belmokhtar
Jean Louis Mergny
Lionel Guittat
Jean Francois Riou
Dennis Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Aventis Pharma SA
Institut Curie
Museum National dHistoire Naturelle
Universite de Reims Champagne Ardenne URCA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Aventis Pharma SA
Institut Curie
Museum National dHistoire Naturelle
Universite de Reims Champagne Ardenne URCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0301478A priority Critical patent/FR2850970B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Aventis Pharma SA, Institut Curie, Museum National dHistoire Naturelle, Universite de Reims Champagne Ardenne URCA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP04708378A priority patent/EP1603898A2/fr
Priority to MXPA05007648A priority patent/MXPA05007648A/es
Priority to CA002514105A priority patent/CA2514105A1/fr
Priority to AU2004210753A priority patent/AU2004210753A1/en
Priority to PCT/FR2004/000260 priority patent/WO2004072027A2/fr
Priority to BRPI0407320-7A priority patent/BRPI0407320A/pt
Priority to JP2006502131A priority patent/JP2006518726A/ja
Priority to US10/773,806 priority patent/US20070232572A1/en
Publication of FR2850970A1 publication Critical patent/FR2850970A1/fr
Application granted granted Critical
Publication of FR2850970B1 publication Critical patent/FR2850970B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0301478A 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique Expired - Fee Related FR2850970B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
MXPA05007648A MXPA05007648A (es) 2003-02-07 2004-02-05 Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.
CA002514105A CA2514105A1 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004210753A AU2004210753A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent
EP04708378A EP1603898A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d adn en g-quadruplexe et leur application comme agent anticancereux specifique
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
BRPI0407320-7A BRPI0407320A (pt) 2003-02-07 2004-02-05 derivados quìmicos que se ligam de maneira muito especìfica às estruturas de dna em g-quadrúples e sua aplicação como agente anticanceroso especìfico
JP2006502131A JP2006518726A (ja) 2003-02-07 2004-02-05 Ｇ四重鎖ｄｎａ構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用
US10/773,806 US20070232572A1 (en) 2003-02-07 2004-02-06 Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Publications (2)

Publication Number Publication Date
FR2850970A1 FR2850970A1 (fr) 2004-08-13
FR2850970B1 true FR2850970B1 (fr) 2006-07-07

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0301478A Expired - Fee Related FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Country Status (8)

Country Link
EP (1) EP1603898A2 (enExample)
JP (1) JP2006518726A (enExample)
AU (1) AU2004210753A1 (enExample)
BR (1) BRPI0407320A (enExample)
CA (1) CA2514105A1 (enExample)
FR (1) FR2850970B1 (enExample)
MX (1) MXPA05007648A (enExample)
WO (1) WO2004072027A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
US8470793B2 (en) 2007-09-25 2013-06-25 Ramot At Tel-Aviv University Ltd. Down-regulation of mortalin by siRNA
WO2009144914A1 (ja) 2008-05-27 2009-12-03 パナソニック株式会社 Ｇ－ｑｕａｄｒｕｐｌｅｘ検出方法、Ｇ－ｑｕａｄｒｕｐｌｅｘ形成ＤＮＡ検出方法およびテロメラーゼ活性測定方法
JP4510929B1 (ja) 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (zh) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515604A (ja) * 1999-11-29 2003-05-07 アベンテイス・フアルマ・ソシエテ・アノニム アリールアミン誘導体およびそれらの抗−テロメラーゼ剤としての使用
FR2819255B1 (fr) * 2001-01-09 2003-02-28 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
JP2004534046A (ja) * 2001-05-28 2004-11-11 アベンティス・ファーマ・ソシエテ・アノニム 化学誘導体および抗テロメラーゼ剤としてのその使用

Also Published As

Publication number Publication date
FR2850970A1 (fr) 2004-08-13
MXPA05007648A (es) 2006-12-15
EP1603898A2 (fr) 2005-12-14
WO2004072027A2 (fr) 2004-08-26
CA2514105A1 (fr) 2004-08-26
WO2004072027A3 (fr) 2004-09-23
BRPI0407320A (pt) 2006-02-21
JP2006518726A (ja) 2006-08-17
AU2004210753A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DK2821085T3 (da) Rna-interferens til behandling af "gain-of-function"-forstyrrelser
IL237721B (en) Lipid-wrapped interfering RNA and uses thereof
FR2850970B1 (fr) Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
MX258070B (es) Compuestos sinteticos utiles como factores de nodulacion de las plantas leguminosas y procedimientos de preparacion de los mismos.
WO2004089947A3 (de) Neue verbindungen mit antibakterieller aktivität
IL175185A0 (en) Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
IL173204A0 (en) Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
TWI347184B (en) Methods of treating hiv infection
EP1633871A4 (en) DOUBLE-STRUCTURED NUCLEIC ACID
EP1752150A4 (en) Irinotecan PREPARATION
MA29015B1 (fr) Agents de liaison specifiques de l'angiopoietine-2
EP1781800A4 (en) PROCESS FOR PLASMID DNA FERMENTATION
DE60108042D1 (de) Prozesse zur Herstellung von pulverförmigen Schlagzäh-Modifizierern
EP2046361A4 (en) OSTEOUS AMPLIFIER COMPOSITION
EP1831238A4 (en) Fluorous oligonucleotide reagents and affinity purification of oligonucleotides
EP1695761A4 (en) CATALYST COMPOSITION
IL179753A0 (en) Process for the preparation of entecavir and novel intermediates thereof via carbon - silicon oxidation
EP1756129A4 (en) NEW INTERCALATORS INTO THE DNA
EP1799875A4 (en) PRODUCTION OF IRON ALLOYS
EP1705247A4 (en) DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND
EP2013366A4 (en) NEW OLIGONUCLEOTIDE PRIMERS AND METHOD FOR DNA REPLICATION
EP1967757A4 (en) RADGEGENGEWICHT
FR2866245B1 (fr) Nouveaux agents epaississants et leur procede de preparation
GB0423991D0 (en) Applications of nucleic acid fragments
IL174325A (en) HIV immunogenic DNA composition

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101029